Clinical trials: Endothelial Progenitor Cells
Coronary Artery Disease, Atherosclerosis
MASCOT - Post Marketing Registry
To collect post marketing surveillance data on patients receiving at least one Combo Bio-Engineered Sirolimus Eluting Stent when used according to the Instructions for Use.
- Trial name
- MASCOT (NCT02183454)
- Testing
- OrbusNeich COMBO stent
- Where
- Netherlands
- Volunteers
- 2,500 people
- Sponsor
- OrbusNeich
Coronary Artery Disease
Deutsches Dual Therapy Stent Register
The DTS.DE registry is an initiative for the collection of high quality process and historical data of implantations with the COMBO Dual Therapy Stent in Germany.
- Trial name
- DTS Register (NCT02102997)
- Where
- Germany
- Volunteers
- 130 people
- Sponsor
- OrbusNeich
Diabetes Mellitus
Efficacy and Safety of Pioglitazone in Treating Subjects With Vascular Complications Associated With Type 2 Diabetes Mellitus.
The purpose of this study is to determine the efficacy of pioglitazone compared to glibenclamide, once daily (QD), taken together with metformin and lifestyle modification in type 2 diabetic subjects with cardiovascular disease.
- Trial name
- SPLENDOR (NCT00770835)
- Testing
- Pioglitazone and Metformin, Glibenclamide and Metformin
- Where
- 2 sites in Italy
- Volunteers
- 39 people
- Sponsor
- Takeda
Endothelial Function, Oxidative Stress
Black Forest Cocoa Flavanol Supplementation and Health Trial
This randomized, double-blind, controlled clinical trial will evaluate the effects of daily cocoa flavanol supplementation on vascular and inflammatory biomarkers in healthy adult men aged 30 to 75 years.
- Conditions
- Endothelial Function, Oxidative Stress, Inflamation, Vascular Health
- Trial name
- NCT07747714
- Testing
- Cocoa Flavanol Supplement, Low-Flavanol Control Powder
- Where
- 2 sites in United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- The Black Forest LLC
Macular Degeneration
A Safety Study in Healthy Volunteers to Evaluate Safety, How Fast the Drug is Absorbed, and the Side Effects of the Drug in Humans
This study is to evaluate the safety, absorption rate and side effects associated with the study drug. Healthy volunteers will be given a single dose of the drug in Part 1.
- Trial name
- NCT01051700
- Testing
- GW786034
- Where
- 3 sites in United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Coronary Artery Lesions
Safety and Effectiveness Study of Combo Bio-engineered Sirolimus Eluting Stent
To demonstrate the safety and effectiveness of the Combo Bio-engineered Sirolimus Eluting Stent (Combo Stent) compared to the Taxus® Liberté® Stent in the treatment of coronary artery lesions.
- Trial name
- REMEDEE (NCT00967902)
- Testing
- coronary stenting
- Where
- Australia
- Volunteers
- 180 people
- Sponsor
- OrbusNeich
Coronary Arteriosclerosis
Safety and Efficacy of the Combo Bio-engineered Sirolimus-eluting Stent Versus the Nano Polymer-free Sirolimus-eluting Stent in the Treatment of Patients With de Novo Stenotic Lesions
To evaluate the safety, efficacy and deliverability of the Combo bio-engineered sirolimus-eluting stent versus the Nano polymer-free sirolimus- eluting stents in the treatment of patients with de novo stenotic lesions of native…
- Trial name
- RECOVERY (NCT02542007)
- Testing
- OrbusNeich Combo stent™, sirolimus-eluting stent system
- Where
- 15 sites in China
- Volunteers
- 440 people
- Sponsor
- OrbusNeich
Coronary Arteriosclerosis, Non ST Segment Elevation Acute Coronary Syndrome
HARMONEE - Japan-USA Harmonized Assessment by Randomized, Multi-Center Study of OrbusNEich's Combo StEnt
This is a multi-center, single-blind, randomized, active-controlled, clinical trial in Percutaneous Coronary Intervention (PCI) subjects.
- Trial name
- HARMONEE (NCT02073565)
- Testing
- OrbusNeich Combo stent™, Everolimus Eluting Stent (EES)
- Where
- 50 sites in United States, Japan
- Volunteers
- 572 people
- Sponsor
- OrbusNeich
Acute Ischemic Stroke
Safety and Preliminary Efficacy of Allogeneic Endothelial Progenitor Cells (EPCs) in Patients With Acute Ischemic Stroke
This is a multicenter, randomized, double-blind, placebo-controlled, dose-Escalation clinical study to investigate the safety and efficacy of EPCs transplantation in Acute ischemic stroke.
- Trial name
- NCT05993884
- Testing
- iEPCs
- Where
- 2 sites in China
- Volunteers
- 27 people
- Sponsor
- Allife Medical Science and Technology Co., Ltd.
Critical Limb Ischemia
Safety and Preliminary Efficacy of Allogeneic Endothelial Progenitor Cells (EPCs) in Patients With Critical Limb Ischemia
The purpose of this study is to determine if allogeneic Endothelial Progenitor Cells (EPCs) intravenous infusion to a subject with leg ulcer and/or gangrene due to poor blood flow will be safe and if it will relieve leg pain…
- Trial name
- NCT06359912
- Testing
- EPCs, Clinical standard treatment (CST)
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Allife Medical Science and Technology Co., Ltd.
Coronary Artery Disease
EPC by Intracoronary Injection in Patients With Chronic Stable Angina
Study title:A Study for Testing Safety and Efficacy of the administration of Blood-Borne Autologous Endothelial Progenitor Cells to Alleviate Anginal Symptoms and Myocardial Ischemia in Patients with Severe Anginal Syndrome…
- Trial name
- NCT00384514
- Testing
- VesCell (TM)-Autologous EPCs/Angiogenic Cell Precursors
- Where
- Israel
- Volunteers
- 24 people
- Sponsor
- TheraVitae Ltd.
Metabolic Disease, Endothelial Dysfunction
Safety and Efficacy Trial Using Allogeneic Human Mesenchymal Stem Cells: The SIRONA Trial
This is a phase 2b, randomized, placebo-controlled clinical trial designed to evaluate the safety and efficacy of Longeveron Mesenchymal Stem Cells (LMSCs) in subjects with metabolic syndrome and to assess the effects of LMSCs on…
- Trial name
- SIRONA (NCT02587572)
- Testing
- Peripheral Intravenous (IV) infusion of LMSCs
- Sponsor
- Longeveron Inc.